Head-to-head evidence
deucravacitinib vs SYHX1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT03611751 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.
Next expected readout: November 2026 · NCT05570955 (registry estimate)
SYHX1901
Developed by CSPC Ouyi Pharmaceutical Co. and partners
NCT05858047 · Phase 2 · completed
The trial randomized 93 participants to placebo or one of three SYHX1901 doses and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical PASI 75 response at week 12, but no results are available to determine whether the comparison was met.
Next expected readout: April 2027 · NCT06943950 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · SYHX1901's landscape